Novartis and others in ‘unprecedented’ COVID-19 partnership
A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
18 June 2020 Switzerland-based Novartis has failed to convince the UK Intellectual Property Office that a trademark applied-for by Boston Healthcare should not be registered.
17 February 2020 Indian drugmaker Zydus Cadila has launched a fast track programme to develop a vaccine for the novel coronavirus COVID-19, which has so far claimed more than 1,600 lives worldwide.
14 February 2020 Johnson & Johnson unit Janssen has expanded an existing R&D agreement with the US Department of Health and Human Services (HHS) as part of efforts to speed up the development of an investigational vaccine for the novel coronavirus COVID-19.